InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 2 February 2024

MoST addendum 19 (substudies 41-42): This phase II study is assessing the effect of targeted therapy (sotorasib) in adults with some advanced cancers that have KRAS G12C mutationsSingle arm, open label, signal-seeking phase II study of Sotorasib (AMG-510) in patients with solid tumours harbouring KRAS G12C mutation

Clinical summary

Summary

This is a substudy of the Cancer Molecular Screening and Therapeutics (MoST) Program (ACTRN12616000908437). Eligible participants will receive 8x oral tablets daily of 120mg Sotorasib, for a total daily dose of 960mg. Tablets will be taken continuously over 28 day cycles until disease progression.

Cancer

Multi-Cancer Multi-Cancer

Age

People18+

Phase

II

Trial Acronym

MoST addendum 19 (substudies 41-42)

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

University of Sydney,Australian Genomic Cancer Medicine Centre (AGCMC)

Scientific Title

Single arm, open label, signal-seeking phase II study of Sotorasib (AMG-510) in patients with solid tumours harbouring KRAS G12C mutation

Eligibility

Inclusion

1. Adults, aged 18 years and older, with pathologically confirmed advanced and/or metastatic solid cancer of any histologic type or an earlier diagnosis of a poor prognosis cancer, identified through the MoST molecular screening program.
2. ECOG performance status 0, 1 or 2;
3. Confirmation of KRAS G12C mutation in the tumour tissue by the next generation sequencing (NGS) panel. Patients who have a positive KRAS G12C mutation determined by a recognised assay may be eligible after discussion with the study chair. Patient should have adequate specimen (archival tissue or biopsy) for full molecular screening;
4. Confirmation of molecular eligibility by the molecular tumour board;
5. Life expectancy greater than or equal to 12 weeks;
6. Received and failed all standard anticancer therapy or have documented unsuitability for any further standard therapy, if standard therapy exists;
7. Clinical or radiological progression on or following last anticancer therapy unless such anticancer therapy stopped due to toxicity / treatment intolerance;
8. Measurable disease as assessed by RECIST 1.1 or RANO;
9. Adequate organ system function as assessed by the following minimal laboratory requirements (within 14 days prior to first administration of study drug):
a. Bone marrow function; platelets greater than or equal to 100 × 109/L, ANC greater than or equal to 1.5 × 109/L, and haemoglobin greater than or equal to 90 g/L;
b. Liver function; ALT/AST less than or equal to 3 × ULN (in the absence of liver metastases, less than or equal to 5 × ULN for patients with liver involvement) and total bilirubin less than or equal to 1.5 × ULN;
10. Renal function; serum creatinine less than or equal to 1.5 × ULN;
11. QTc less than or equal to 470 msec (based on average of screening triplicates)
12. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments
13. Signed, written informed consent to participation in the specific treatment substudy.

Exclusion

1. Contraindications to investigational product;
2. Known history of hypersensitivity to active or inactive components of investigational product;
3. History of prior KRAS G12C inhibitor treatment. Prior treatment or participation in a clinical trial with an inhibitor of Mitogen-activated protein kinase (MAPK) or other KRAS-targeting agent is allowed;
4. Patients with non-small cell lung cancer (NSCLC) or colorectal cancer are ineligible;
5. Specific comorbidities or conditions (e.g., psychiatric) or concomitant medications which may interact with the investigational product;
6. Co-morbidities or conditions that may compromise assessment of key outcomes or in the opinion of the clinician, limit the ability of the patient to comply with the protocol;
7. Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment:
a. Radiation therapy, major surgery, or tumour embolization within 14 days prior to the first dose of study treatment. Palliative radiotherapy (for analgesia) is acceptable only if the irradiated field does not include target lesions;
b. Immunotherapy within 28 days prior to the first dose of study treatment;
c. Chemotherapy, biologic therapy or hormonal therapy within 28 days of a drug prior to the first dose of study treatment or until recovery from previous therapy (whichever is longer);
d. Any unresolved toxicity (greater than CTCAE grade 2) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included;
8. Administration of any investigational treatment within 28 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study treatment;
9. Use of any of the following agents within 14 days or 5 half-lives of the drug or its major active metabolite, whichever is longer, prior to study day 1 that was not reviewed and approved by the principal investigator: (1) known cytochrome P450 CYP3A4 sensitive or P-gp substrates with a narrow therapeutic window, (2) strong inhibitors of CYP3A4, (3) grapefruit juice or grapefruit containing products, (4) strong inducers of CYP3A4 (including St. John's wort)
10. For non-central nervous system (CNS) cancers, patients with symptomatic CNS involvement of his/her cancer are excluded. Subjects with stable neurological function, on stable doses of steroids/anti-epileptics over 4 weeks, and with no evidence of CNS progression within 12 weeks prior to screening are eligible;
11. Active hepatitis infection based on the following results and/or criteria:
a. Positive Hepatitis B Surface Antigen (HBsAg);
b. Negative HBsAg with a positive for hepatitis B core antibody (HBcAb);
c. Positive Hepatitis C virus antibody: Hepatitis C virus RNA by PCR is necessary. Detectable Hepatitis C virus RNA suggests chronic hepatitis C;
12. Known positive test for HIV;
13. Prior or concurrent malignancy. For participants with treatment-refractory solid tumours, a concurrent or past history of competing malignancy within 2 years, prior to molecular screening registration, is eligible, unless the competing malignancy is expected to lead to a shorter survival than the index KRAS G12C-harbouring malignancy;
14. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Hormonal-based contraception are not allowed. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilized or use a (double if required) barrier method of contraception.

Inclusion

  • You are able to swallow medication by mouth.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

Exclusion

  • You have been diagnosed with a prior or secondary type of cancer.
  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.
Message

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support

Example

Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more

Example

Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more

Example

Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.

RAP

Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.